← Leaderboards
Karen S Marder
Columbia University Health Sciences
$15,291,810
Attributed
$20,603,207
Total exposure
19
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,603,207 · 19
By mechanism
R01$6,789,012 · 1
U01$4,520,736 · 1
U24$2,923,323 · 1
M01$2,516,993 · 13
U10$2,204,295 · 1
P01$1,148,848 · 1
Top collaborators
- Claudia A Chiriboga15 shared
- Lawrence S Honig5 shared
- Susan A Gauthier3 shared
- Harini Sarva3 shared
- Claire Henchcliffe2 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Claudia A Chiriboga$5,375,833
- Lorraine N Clark$7,054,136
- Yaakov Stern$60,326,200
- Willard Allen Hauser$3,055,238
- Ralph Lewis Sacco$56,271,933
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectEnrollmentNational Institute Of Neurological Disorders And StrokeDesignMethodologyFamilySiteBiomarkerBiological MarkersResearch PersonnelCognition DisordersClinical TrialsResourcesCommunitiesProgramsParticipantFoundationsAdultCollaborationsFacultyChildhoodAdvocateMedical Schools
Grant awards (74)
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)$439,931
U24 · FY2025 · NS · contact PI
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)$433,251
U24 · FY2024 · NS · contact PI
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)$469,300
U24 · FY2023 · NS · contact PI
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)$301,140
U24 · FY2022 · NS · contact PI
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)$306,816
U24 · FY2021 · NS · contact PI
Targeting Lewy Body Specific Pathology Using Biomarkers$907,896
U01 · FY2020 · NS · contact PI
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)$313,296
U24 · FY2020 · NS · contact PI
Targeting Lewy Body Specific Pathology Using Biomarkers$1,044,669
U01 · FY2019 · NS · contact PI
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)$322,574
U24 · FY2019 · NS · contact PI
Targeting Lewy Body Specific Pathology Using Biomarkers$950,555
U01 · FY2018 · NS · contact PI
Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)$337,015
U24 · FY2018 · NS · contact PI
Targeting Lewy Body Specific Pathology Using Biomarkers$844,960
U01 · FY2017 · NS · contact PI
Columbia University Medical Center - Weill Cornell Medical Center NEXT Site$320,817
U10 · FY2017 · NS · contact PI
Targeting Lewy Body Specific Pathology Using Biomarkers$772,656
U01 · FY2016 · NS · contact PI
Columbia University Medical Center - Weill Cornell Medical Center NEXT Site$320,817
U10 · FY2016 · NS · contact PI
Columbia University Medical Center - Weill Cornell Medical Center NEXT Site$320,817
U10 · FY2015 · NS · contact PI
Columbia University Medical Center - Weill Cornell Medical Center NEXT Site$274,220
U10 · FY2014 · NS · contact PI
Columbia University Medical Center - Weill Cornell Medical Center NEXT Site$314,325
U10 · FY2013 · NS · contact PI
Columbia University Medical Center - Weill Cornell Medical Center NEXT Site$323,465
U10 · FY2012 · NS · contact PI
Columbia University Medical Center - Weill Cornell Medical Center NEXT Site$329,834
U10 · FY2011 · NS · contact PI
Genetic Epidemiology of Parkinson's Disease$500,000
R56 · FY2010 · NS · contact PI
Genetic Epidemiology of Parkinson's Disease$1,036,360
R01 · FY2008 · NS · contact PI
Genetic Epidemiology of Parkinson's Disease$1,082,765
R01 · FY2007 · NS · contact PI
Genetic Epidemiology of Parkinson's Disease$1,098,704
R01 · FY2006 · NS · contact PI
Genetic Epidemiology of Parkinson's Disease$1,101,278
R01 · FY2005 · NS
PILOT HUNTINGTON'S AT RISK OBSERVATIONAL STUDY (PHAROS)$14,516
M01 · FY2005 · RR
PREDICT-HD$4,516
M01 · FY2005 · RR
SELEGILINE TRANSDERMAL SYSTEM$2,233
M01 · FY2005 · RR
Genetic Epidemiology of Parkinson's Disease$1,089,898
R01 · FY2004 · NS
Neurocognitive Function, HIV Load and Surrogate Markers$31,967
M01 · FY2004 · RR
SELEGILINE TRANSDERMAL SYSTEM$10,202
M01 · FY2004 · RR
Pilot Huntington's at Risk Observational Study (PHAROS)$9,720
M01 · FY2004 · RR
PREDICT-HD$4,443
M01 · FY2004 · RR
CREST$2,777
M01 · FY2004 · RR
Genetic Epidemiology of Parkinson's Disease$531
M01 · FY2004 · RR
GENETIC EPIDEMIOLOGY OF PARKINSONS DISEASE$50,000
R01 · FY2003 · NS
PLASMA VIRAL LOAD AND COGNITIVE DECLINE IN ADVANCED HIV INFECTION$282,412
P01 · FY2002 · NS
PLASMA VIRAL LOAD AND COGNITIVE DECLINE IN ADVANCED HIV INFECTION$282,412
P01 · FY2002 · NS
PILOT HUNTINGTON'S AT RISK OBSERVATIONAL STUDY (PHAROS)$192,910
M01 · FY2002 · RR
PILOT EFFICACY STUDY OF CPI 1189 IN HIV INFECT INDIV W/ COGNIT &MOTO$192,910
M01 · FY2002 · RR
GENETIC EPIDEMIOLOGY OF PARKINSONS DISEASE$192,910
M01 · FY2002 · RR
NEUROCOGNITIVE FUNCTION, HIV LOAD &SURROGATE MARKERS$192,910
M01 · FY2002 · RR
CO-ENZYME Q10 AND REMACEMIDE--EVALUATION IN HUNTINGTON'S DISEASE$192,910
M01 · FY2002 · RR
PHASE III TRIAL OF 1592U89 IN HIV-1 PATIENTS WITH AIDS DEMENTIA$192,910
M01 · FY2002 · RR
GENETIC EPIDEMIOLOGY OF PARKINSONS DISEASE$651,104
R01 · FY2001 · NS
PLASMA VIRAL LOAD AND COGNITIVE DECLINE IN ADVANCED HIV INFECTION$282,412
P01 · FY2001 · NS
PILOT EFFICACY STUDY OF CPI 1189 IN HIV INFECT INDIV W/ COGNIT &MOTO$192,910
M01 · FY2001 · RR
PILOT HUNTINGTON'S AT RISK OBSERVATIONAL STUDY (PHAROS)$192,910
M01 · FY2001 · RR
GENETIC EPIDEMIOLOGY OF PARKINSONS DISEASE$192,910
M01 · FY2001 · RR
NEUROCOGNITIVE FUNCTION, HIV LOAD &SURROGATE MARKERS$192,910
M01 · FY2001 · RR
CO-ENZYME Q10 AND REMACEMIDE--EVALUATION IN HUNTINGTON'S DISEASE$192,910
M01 · FY2001 · RR
PHASE III TRIAL OF 1592U89 IN HIV-1 PATIENTS WITH AIDS DEMENTIA$192,910
M01 · FY2001 · RR
GENETIC EPIDEMIOLOGY OF PARKINSONS DISEASE$50,000
R01 · FY2001 · NS
PHASE III TRIAL OF 1592U89 IN HIV-1 PATIENTS WITH AIDS DEMENTIA$0
M01 · FY2001 · RR
NEUROCOGNITIVE FUNCTION, HIV LOAD &SURROGATE MARKERS$0
M01 · FY2001 · RR
CO-ENZYME Q10 AND REMACEMIDE--EVALUATION IN HUNTINGTON'S DISEASE$0
M01 · FY2001 · RR
GENETIC EPIDEMIOLOGY OF PARKINSONS DISEASE$0
M01 · FY2001 · RR
PILOT HUNTINGTON'S AT RISK OBSERVATIONAL STUDY (PHAROS)$0
M01 · FY2001 · RR
PILOT EFFICACY STUDY OF CPI 1189 IN HIV INFECT INDIV W/ COGNIT &MOTO$0
M01 · FY2001 · RR
GENETIC EPIDEMIOLOGY OF PARKINSONS DISEASE$628,903
R01 · FY2000 · NS
PLASMA VIRAL LOAD AND COGNITIVE DECLINE IN ADVANCED HIV INFECTION$301,612
P01 · FY2000 · NS
SELEGILINE TRANSDERMAL SYSTEM TREATMENT OF HIV ASSOCIATED COGNITIVE IMPAIRMENT$121,168
M01 · FY2000 · RR
PHASE III TRIAL OF 1592U89 IN HIV-1 PATIENTS WITH AIDS DEMENTIA$0
M01 · FY2000 · RR
PILOT HUNTINGTON'S AT RISK OBSERVATIONAL STUDY (PHAROS)$0
M01 · FY2000 · RR
PILOT HUNTINGTON'S AT RISK OBSERVATIONAL STUDY (PHAROS)$0
M01 · FY2000 · RR
PILOT EFFICACY STUDY OF CPI 1189 IN HIV INFECT INDIV W/ COGNIT &MOTO$0
M01 · FY2000 · RR
PILOT EFFICACY STUDY OF CPI 1189 IN HIV INFECT INDIV W/ COGNIT &MOTO$0
M01 · FY2000 · RR
GENETIC EPIDEMIOLOGY OF PARKINSONS DISEASE$0
M01 · FY2000 · RR
GENETIC EPIDEMIOLOGY OF PARKINSONS DISEASE$0
M01 · FY2000 · RR
NEUROCOGNITIVE FUNCTION, HIV LOAD &SURROGATE MARKERS$0
M01 · FY2000 · RR
NEUROCOGNITIVE FUNCTION, HIV LOAD &SURROGATE MARKERS$0
M01 · FY2000 · RR
CO-ENZYME Q10 AND REMACEMIDE--EVALUATION IN HUNTINGTON'S DISEASE$0
M01 · FY2000 · RR
CO-ENZYME Q10 AND REMACEMIDE--EVALUATION IN HUNTINGTON'S DISEASE$0
M01 · FY2000 · RR
PHASE III TRIAL OF 1592U89 IN HIV-1 PATIENTS WITH AIDS DEMENTIA$0
M01 · FY2000 · RR